Spero Therapeutics (SPRO) FCF Margin Growth (5y) (2021 - 2026)
Powered by 
Analysis
Spero Therapeutics (SPRO) FCF Margin Growth (5y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.47 Bn | 193.48 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.76 Bn | 175.58 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.10 Bn | 55.91 Bn | 1.37 Bn |
| 6 | Moderna | 53.44 Bn | 48.30 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.55 Bn | 30.24 Bn | 992.69 Mn |
| 8 | Biogen | 31.67 Bn | 30.39 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.63 Bn | 29.63 Bn | 1.16 Mn |
| 10 | Spero Therapeutics | 66.95 Mn | 16.18 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 636,088.00 |
| Dec 31, 2025 | 83,951.00 |
| Sep 30, 2025 | 85,368.00 |
| Jun 30, 2025 | 131,775.00 |
| Mar 31, 2025 | 130,800.00 |
| Dec 31, 2024 | 235,824.00 |
| Sep 30, 2024 | 30,316.00 |
| Jun 30, 2024 | 38,005.00 |
| Mar 31, 2024 | 20,667.00 |
| Dec 31, 2023 | 91,728.00 |
| Sep 30, 2023 | 90,047.00 |
| Jun 30, 2023 | 118,280.00 |
| Mar 31, 2023 | 41,616.00 |
| Dec 31, 2022 | 137,664.00 |
| Sep 30, 2022 | 171,360.00 |
| Jun 30, 2022 | 240,937.00 |
| Mar 31, 2022 | 362,091.00 |
| Dec 31, 2021 | -1.56 Mn |